Tenax Therapeutics TENX Insider Ownership

Updated Oct 22, 2026

Over the past year, TENX insiders bought $6.59 million of stock (3.71Mn shares) on the open market and sold none.

• Behind Tenax Therapeutics' open-market purchases in the past 12 months were 7 insiders, and no insider sold.
• Among Tenax Therapeutics' insiders, the largest open-market purchases in the past 12 months were by Adar1 Capital Management, LLC (10% owner), totaling $6.26 million (3.62Mn shares), most recently on October 21, 2026.
• Apart from open-market trades, TENX insiders received 10K shares in stock awards and acquired 8.72K shares through option exercises and conversions in the past 12 months.
• According to Business Quant data, insiders at Tenax Therapeutics reported 7.57Mn shares in total in their latest Form 4 filings.
• Direct holdings account for 106.93K shares (1.41%) of TENX's insider total, and indirect holdings through trusts, partnerships and family members for 7.46Mn shares (98.59%).
• TENX's insider total is spread across 9 insiders who have filed a Form 4 in the past two years.
• Tenax Therapeutics' three biggest insider holders are Adar1 Capital Management, LLC (10% owner, 7.45Mn shares), Declan Doogan (Director, 55.27K shares) and Christopher Thomas Giordano (CEO, 22.17K shares), based on their latest Form 4 filings.
• Of the shares held by TENX insiders, 98.38% belong to Adar1 Capital Management, LLC.
• Institutions accounted for 59.64% of TENX's outstanding shares in Q2 2026, insiders about 14.88% per their latest Form 4 filings, and other investors, including the public, about 25.48%.
• A total of 23 Form 4 filings with transactions in Tenax Therapeutics stock were made over the past 12 months, by 10 insiders.
• These insider figures for Tenax Therapeutics are based on Form 4 filings through October 21, 2026.